SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

IME ImExHS Limited

Healthcare · Diagnostics & Research · website · 290 employees
$0.33
52wk 0.23 – 0.47
Overall
41.5
Value
33.7
Growth
76.2
Health
55.4
Quality
4.7
Momentum
23.9
Dividend
—
Price
About ImExHS Limited

ImExHS Limited offers cloud-based medical imaging solutions in Australia and internationally. The company operates in two segments: Software and Radiology. It offers medical imaging software that is focused on the development and sale of modular imaging systems, which include information systems for radiology, cardiology, and pathology, as well as a picture archiving and communications system. The company's solutions include AQUILA, a radiology software solution; ALULA, a pathology software solution; and ANTEROS, a cardiology software solution. It also provides radiological diagnostic services to hospitals and medical facilities; medical images and radiologists' interpretation; reports to develop artificial intelligence (AI) tools; and outsourced radiology services, as well as teleradiology services. ImExHS Limited was incorporated in 2001 and is based in Sydney, Australia.

Price analytics

Returns

1 day 0.0%
1 week 0.0%
1 month -8.5%
3 months -5.8%
6 months -16.7%
1 year 25.0%
3 years -44.0%

Risk

Volatility (1y ann.) 63.3%
Beta vs ASX 200 -0.23
Sharpe (1y) 0.60
VaR 95% (1-day) -7.0%
Max drawdown (1y) -40.4%
Off 1-year high -30.9%

Technicals

RSI(14) 50
vs 50DMA 1.7%
vs 200DMA -11.3%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 33.7
Trailing P/E
23
Forward P/E
0
PEG ratio
—
EV / EBITDA
0
Price / Book
97
Price / Sales
100
Growth 76.2
Revenue growth (1y)
56
Revenue CAGR (3y)
97
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 55.4
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
55
Debt / Equity
100
Quality (Profitability & Cash Flow) 4.7
Return on equity
6
Return on assets
5
Operating margin
3
Net margin
4
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 23.9
6-month return vs ASX 200
0
Price vs 200-day average
12
Price vs 50-day average
59
Position in 52-week range
40

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$17.68M
P/E (trailing)
32.50
P/E (forward)
45.52
EPS (trailing)
0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.81
EV / EBITDA
30.82
Price / Book
1.03
ROE
1.2%
Operating margin
0.9%
Net margin
0.6%
Total cash
$1.99M
Total debt
$455,338
Current ratio
1.73
Debt / Equity
0.03
Free cash flow
$-672,039
Avg volume
6,236
Latest annual results (FY ending 31 Dec 2025)
  • Revenue$28.97M
  • Gross profit$28.97M
  • Operating income-$897.19K
  • Net income-$2.88M
  • Diluted EPS-0.06
  • Free cash flow-$677.88K
  • Net debt-$2.73M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4